Dr. John Cush RheumNow
2 years 1 month ago
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Dr. John Cush RheumNow
2 years 1 month ago
Personalized Exercise may have Key Benefits in AxSpa
At EULAR, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for people with AxSpA and severe functional limitations.
https://t.co/TUP6hoLgJ4 https://t.co/t1gNQBdFzh
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without
Dr. John Cush RheumNow
2 years 1 month ago
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/58cJsSROsE to stay at the forefront of medical innovation. https://t.co/jbbufRQ6MW
Dr. John Cush RheumNow
2 years 2 months ago
Rituximab vs. Tocilizimab for Scleroderma: Which is Better?
Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria.
https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u
Dr. John Cush RheumNow
2 years 2 months ago
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW
Dr. John Cush RheumNow
2 years 2 months ago
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ
Dr. John Cush RheumNow
2 years 2 months ago
Damage in Childhood Lupus
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh
Dr. John Cush RheumNow
2 years 2 months ago
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2
Dr. John Cush RheumNow
2 years 2 months ago
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF
Dr. John Cush RheumNow
2 years 2 months ago
EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn
Dr. John Cush RheumNow
2 years 2 months ago
Rituximab to Treat Systemic Features of Sjogren's
Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria.
https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9
Dr. John Cush RheumNow
2 years 2 months ago
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
